Cargando…
Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and its incidence is increasing. PDAC often shows resistance to several therapeutic modalities and a higher recurrence rate after surgical treatment in the early localized stage. Combination chemotherapy in advanced...
Autores principales: | Won, Eun-Jeong, Park, Hyeji, Yoon, Tae-Jong, Cho, Young-Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780888/ https://www.ncbi.nlm.nih.gov/pubmed/35057033 http://dx.doi.org/10.3390/pharmaceutics14010137 |
Ejemplares similares
-
Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
por: Jain, Aditi, et al.
Publicado: (2021) -
Prognostic Significance of Maspin in Pancreatic Ductal Adenocarcinoma
por: Lim, Yun Jeong, et al.
Publicado: (2004) -
Prognostic Value of VEGF in Human Pancreatic Ductal Adenocarcinoma
por: Lim, Yun Jeong, et al.
Publicado: (2004) -
Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges
por: Poh, Ashleigh R., et al.
Publicado: (2021) -
Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)